. 2017 Nov 1;17(16):1–86.

Table 6:

Results of Economic Literature Review—Summary

				Results
Name, Year, Location	Study Design and Perspective	Population	Interventions/Comparators	Health Outcomes	Costs	Cost-Effectiveness
Gerth et al, 2014,¹¹ Canada	Type of economic analysis: CMA Study design: CMA model Perspective:: Public payer Time horizon: 1 year	Patients with primary and secondary immunodeficiency	SCIG IVIG	NA	First year SCIG: $691; IVIG: $3,292 Subsequent years SCIG: $345; IVIG: $3,292 Cost year: 2011 Note: Only nursing time was included.	SCIG led to substantial cost-saving
Martin et al, 2013,³⁴ Canada	Type of economic analysis: CMA Study design: CMA model Perspective: : Public payer Time horizon: 3 year	Adults with primary immunodeficiency	SCIG by manual rapid push IVIG	NA	SCIG: $1,978; IVIG: $7,714 Cost year: 2011 Note: 1) drug cost was not included and 2) discounting was not applied	SCIG led to substantial cost-saving
Ho et al, 2008,³⁵ Canada (first analysis)^a	Type of economic analysis: CMA Study design: CMA model Perspective: Public payer Time horizon: 1 year	Adults and children with primary immunodeficiency	SCIG by pump Infusion administration IVIG	NA	Adult (70 kg) SCIG: $20,417; IVIG: $21,777 Children (40 kg) SCIG: $12,101; IVIG: $13,460 Cost year: 2007	SCIG led to slight cost-saving
Ho et al, 2008,³⁵ Canada (second analysis)^b	Type of economic analysis: CUA Study design: Decision-analytic model Perspective: : Public payer Time horizon: 1 year	Adults with primary immunodeficiency	SCIG by pump Infusion Administration IVIG	SCIG: 0.675 QALY IVIG: 0.648 QALY	Adult (70 kg) SCIG: $20,065; IVIG: $21,273 Cost year: 2007	SCIG dominated IVIG with lower cost and higher QALY
Beaute et al2010,³⁶ France (first analysis)^a	Type of economic analysis: CMA Study design: CMA model Perspective: : French social insurance Time horizon: 1 year	Patients with primary immunodeficiency	SCIG by pump Infusion Administration IVIG	NA	Model (50 kg young adult) SCIG: €24,952; IVIG: €25,583 Cost year: not reported	SCIG led to a slight cost-saving
Beaute et al2010,³⁶ France (second analysis)^c	Type of economic analysis: CMA Study design: cohort study Perspective: French social insurance Time horizon: 1 year	Patients with primary immunodeficiency	SCIG by pump Infusion Administration IVIG	NA	Individual level data in the cohort (SCIG: 15.2 years old and 40 kg; IVIG: 15.6 years old and 41.8 kg) SCIG: €20,289 (IG cost: €12,935); IVIG: €26,428 (IG cost: €18,703) Cost year: Not reported	SCIG showed substantial savings due to lower dose prescribed of IG

Abbreviations: CUA, cost-utility analyses; CMA, cost minimization analysis; IG, immunoglobulin; IVIG, hospital-based intravenous immunoglobulin; NA, not applicable; QALY, quality-adjusted life year; SCIG, home-based subcutaneous immunoglobulin.

For the first analysis (cost minimization), authors assumed that SCIG and IVIG would yield identical clinical outcomes.

For the second analysis (cost utility), authors assumed that SCIG and IVIG would yield different clinical outcomes.

Authors include eight patients with SCIG therapy and 26 patients with IVIG therapy. The crude results are reported.